Euroespes S.A. (EEP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Euroespes S.A. (EEP) has a cash flow conversion efficiency ratio of 0.003x as of December 2022. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€16.87K ≈ $19.72K USD) by net assets (€6.20 Million ≈ $7.25 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Euroespes S.A. (EEP) defensive interval to measure how many days the company can operate on defensive assets alone.
Euroespes S.A. - Cash Flow Conversion Efficiency Trend (2010–2024)
This chart illustrates how Euroespes S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Euroespes S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Euroespes S.A. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
iDimension Consolidated Bhd
KLSE:0174
|
0.001x |
|
SIMFABRIC SA ZY-10
F:853
|
0.139x |
|
Cooper Metals Ltd
AU:CPM
|
-0.020x |
|
Mears Group plc
LSE:MER
|
0.354x |
|
Kane Biotech Inc
V:KNE
|
0.912x |
|
Indaptus Therapeutics Inc
NASDAQ:INDP
|
-1.012x |
|
RENFORTH RESS. INC. NEW
F:9RR
|
0.400x |
|
International Lithium Corp
V:ILC
|
-0.028x |
Annual Cash Flow Conversion Efficiency for Euroespes S.A. (2010–2024)
The table below shows the annual cash flow conversion efficiency of Euroespes S.A. from 2010 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Euroespes S.A..
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €2.57 Million ≈ $3.01 Million |
€70.53K ≈ $82.45K |
0.027x | -85.74% |
| 2023-12-31 | €2.89 Million ≈ $3.38 Million |
€556.08K ≈ $650.12K |
0.192x | +284.10% |
| 2022-12-31 | €6.20 Million ≈ $7.25 Million |
€-647.82K ≈ $-757.37K |
-0.104x | -4775.18% |
| 2021-12-31 | €7.43 Million ≈ $8.68 Million |
€16.60K ≈ $19.41K |
0.002x | +105.78% |
| 2020-12-31 | €7.44 Million ≈ $8.70 Million |
€-287.52K ≈ $-336.15K |
-0.039x | +43.58% |
| 2019-12-31 | €7.45 Million ≈ $8.71 Million |
€-510.28K ≈ $-596.57K |
-0.068x | -1425.55% |
| 2018-12-31 | €8.80 Million ≈ $10.29 Million |
€45.47K ≈ $53.16K |
0.005x | -97.41% |
| 2017-12-31 | €4.57 Million ≈ $5.34 Million |
€911.75K ≈ $1.07 Million |
0.200x | +88.63% |
| 2016-12-31 | €4.26 Million ≈ $4.98 Million |
€451.25K ≈ $527.55K |
0.106x | -21.39% |
| 2015-12-31 | €3.08 Million ≈ $3.60 Million |
€414.91K ≈ $485.07K |
0.135x | +302.30% |
| 2014-12-31 | €2.75 Million ≈ $3.21 Million |
€91.88K ≈ $107.42K |
0.033x | +45.12% |
| 2010-12-31 | €3.98 Million ≈ $4.66 Million |
€91.88K ≈ $107.42K |
0.023x | -- |
About Euroespes S.A.
Euroespes, S.A., a medical center, provides medical services for the research, diagnosis, and treatment of central nervous system disorders and other diseases in Spain and internationally. It offers personalized and genomic medicine services for predictive, diagnostic, and therapeutic purposes. The company also provides medical services, such as neuro-ophthalmology, neuro-otorhinolaryngology, neu… Read more